ArticleJACC. Asia2024
Initial Results of Intra-Annular Self-Expandable Valves: Insights From the OCEAN-TAVI Registry.
Article in JACC. Asia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- Prosthesis-Patient Mismatch in All-Comer Patients Undergoing Newer-Generation Self-Expanding Transcatheter Aortic Valve Replacement.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
- Assessment of Implantation With Intra-Annular Self-Expandable Device in Transcatheter Aortic Valve Replacement.JACC. Asia · 2026Article
- New-Onset Left Bundle Branch Block After TAVI: An Updated Review.Journal of clinical medicine · 2026Review
- Pacemaker Implantation Rates With the Self-Expandable Navitor Valve.Journal of the American Heart Association · 2026Article
- Midterm Outcomes of the Self-Expanding Navitor Transcatheter Heart Valve: A Systematic Review and Meta-Analysis.Structural heart : the journal of the Heart Team · 2026Article
- Incidence and Predictors of Valve Pop-up During Navitor Valve Implantation.Circulation reports · 2025Article
- The TAVI Dilemma: Balloon-Expandable or Self-Expanding Transcatheter Heart Valve-Interpreting Current Evidence for Personalized Valve Selection.Journal of clinical medicine · 2025Review
- Intra- versus supra-annular self-expanding transcatheter heart valves in small aortic annuli.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Article
- Early clinical outcomes of transcatheter aortic valve implantation using the NAVITOR system.Cardiovascular intervention and therapeutics · 2025Article
- Clinical Implications of Good Post-TAVR Echocardiographic Hemodynamics: Do We Know Enough?JACC. Asia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Navitor, an intra-annular self-expanding heart valve (IA-SEV), is the third transcatheter heart valve introduced in Japan (in April 2022) as the next generation of the Portico valve ahead of other Asian countries. Objectives: The purpose of this study was to assess the patient-prosthesis mismatch (PPM) after IA-SEV implantation in Asian patients. Methods: All clinical data were collected from the database of an ongoing prospective Japanese multicenter registry (OCEAN-TAVI [Optimised Catheter Valvular Intervention transcatheter aortic valve implantation]). The primary endpoint was the rate of no PPM; the secondary endpoint included the rate of in-hospital mortality and hemodynamics after IA-SEV implantation. Results: A total of 463 patients (median age 86; 69.7% female) were enrolled in the registry. The percentages of implanted valves sized 23 mm, 25 mm, 27 mm, and 29 mm were 26.1% (n = 121), 41.7% (n = 193), 22.9% (n = 106), and 9.3% (n = 43), respectively. The primary endpoint of no PPM was achieved in 91.7% of the entire cohort and in 87.3%, 94.2%, 91.4%, and 93.0% of each valve size. The rate of in-hospital mortality was 1.9%. Postprocedural mean pressure gradient was 8.3 ± 4.3 mm Hg. The overall rate of pacemaker implantation was 9.7%; the incidence of pacemaker rate tended to be reduced when dividing the first and second half of operator experiences (13.0% vs. 8.0%; Conclusions: The initial results for the IA-SEV were excellent regarding hemodynamics and reduction of paravalvular leakage regardless of valve size. The IA-SEV is a useful transcatheter heart valve, especially for Asian patients with a high prevalence of small annulus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.